New Aromatic Bisabolane Derivatives with Lipid-Reducing Activity from the Marine Sponge Myrmekioderma sp.

Publisher's version (útgefin grein) The previously reported 1-(2,4-dihydroxy-5-methylphenyl)ethan-1-one (1), (1’Z)-2-(1’,5’-dimethylhexa-1’,4’-dieny1)-5-methylbenzene-1,4-diol (2), and 1,8-epoxy-1(6),2,4,7,10-bisaborapentaen-4-ol (5) together with four new structures of aromatic bisabolane-rela...

Full description

Bibliographic Details
Published in:Marine Drugs
Main Authors: Costa, Margarida, Coello, Laura, Urbatzka, Ralph, Pérez, Marta, Thorsteinsdóttir, Margrét
Other Authors: Lyfjafræðideild (HÍ), Faculty of Pharmaceutical Sciences (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland
Format: Article in Journal/Newspaper
Language:English
Published: MDPI AG 2019
Subjects:
Bioactivity
Bisabolane-related compounds
Marine sponges
Natural compounds
Obesity
Whole small animal models
Náttúruefni (lyfjafræði)
Svampdýr
Offita
Lyfjaefnafræði
Iceland
Online Access:https://hdl.handle.net/20.500.11815/2048
https://doi.org/10.3390/md17060375
Description
Summary:Publisher's version (útgefin grein) The previously reported 1-(2,4-dihydroxy-5-methylphenyl)ethan-1-one (1), (1’Z)-2-(1’,5’-dimethylhexa-1’,4’-dieny1)-5-methylbenzene-1,4-diol (2), and 1,8-epoxy-1(6),2,4,7,10-bisaborapentaen-4-ol (5) together with four new structures of aromatic bisabolane-related compounds (3, 4, 6, 7) were isolated from the marine sponge Myrmekioderma sp. Compounds 1, 2, and 5 were identified based on spectral data available in the literature. The structures of the four new compounds were experimentally established by 1D and 2D-NMR and (−)-HRESIMS spectral analysis. Cytotoxic and lipid-reducing activities of the isolated compounds were evaluated. None of the isolated compounds were active against the tested cancer cell lines; however, lipid-reducing activity was found for compounds 2–5 and 7 in the zebrafish Nile red fat metabolism assay. This class of compounds should be further explored for their suitability as possible agents for the treatment of lipid metabolic disorders and obesity. View Full-Text Funding: The research leading to these results received funding from the Marie Curie Actions of the European Union’s Seventh Framework Programme FP7/2007-2013/ under REA grant agreement No. 607786, BluePharmTrain, and by the European ERA-NET Marine Biotechnology project CYANOBESITY (ERA-MBT/0001/2015), financed by national funds through FCT (Foundation for Science and Technology, Portugal), RANNIS (Icelandic Center of Research, Iceland), and FCT strategic fund UID/Multi/04423/2019. Ralph Urbatzka was supported by FCT grant SFRH/BPD/112287/2015. Peer Reviewed

Similar Items